miRNAs may be a tool to address the challenges that CAR–T-cells face, because miRNAs can control tumor antigenicity, amplify T-cell responses, expand CTLs and anti-tumorigenic CD4+ T cells, increase T-cell infiltration into the TME, and counteract the effects of immunosuppression. This evidence concerns the gene CD4 and neoplasm.